Navigation Links
Cardiome Announces Management Transition
Date:8/3/2009

uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.


'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
2. Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
3. Cardiome Reports First Quarter Results
4. Cardiome to Hold Conference Call
5. CardioCareLive.com, First Ever Online Cardiometabolic Conference, Revolutionizes Continuing Medical Education for Cardiovascular Healthcare Professionals
6. Cardiome Reports 2008 Results
7. CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today
8. Noninvasive Medical Technologies to Exhibit at CardioCareLive - A Premier Cardiometabolic Conference
9. Cardiome Discloses Chairman And CEOs Involuntary Share Sale
10. Cardiome Provides Regulatory Update
11. Cardiome To Release Second Quarter Results And Hold Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue ... -- significantly reduce the risk of vision loss in ... British researchers led by David Garway-Heath, of the ... London, tracked outcomes for more than 500 people newly ... of the disease and one of the leading causes ...
(Date:12/17/2014)... Myo Nwe is the co-author of a new weight loss ... of the Ace Medical Weight Loss Center in Rock Hill, ... at the industry of weight loss, and how several fad ... in television shows, however, she says the topic of obesity ... for basic laughs, which she believes impacts whether Americans view ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one of ... variability (HRV), heart coherence and the physiology of ... and algorithms to chipset manufacturers and consumer electronics ... to offer its HRV solutions, tap into its ... its normative HRV databases and algorithms for developing ...
(Date:12/17/2014)... 17, 2014 No matter how far ... to eradicate the head louse parasite—a common childhood malady ... Each year between six and twelve million individuals will ... lice removal treatment company comes to the rescue, providing ... friendly. With its track record of customer service, and ...
(Date:12/17/2014)... MONDAY, Dec. 15, 2014 (HealthDay News) -- As gas ... and deaths, a new study suggests. In times ... many of those riders are inexperienced, the researchers explained. ... in California, which has the highest number of motorcycle ... number of motorcyclist deaths. The analysis revealed a ...
Breaking Medicine News(10 mins):Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2
... first astronaut, involved in a 25 million dollar space ... on the growth of cancer cells in outer space, ... conduct research on cells, bacteria and the crystallisation of ... Molecule Medical Institute at the National University of Malaysia. ...
... College London have found that injections of stem cells ... of children with brittle bone disease , osteogenesis imperfecta ... foetuses by DNA testing or ultrasound, disrupts collagen production, ... the condition suffer fractures while in the womb, and ...
... on Wednesday proposed uprooting excess vineyards and launching an ... strategy aimed at soaking up glut and countering New ... that the European Union's annual wine budget of 1.3 ... "a very inefficient way" despite huge challenges facing the ...
... cat allergen is associated with greater bronchial responsiveness (BR) ... they are not specifically allergic to cats. This suggests ... allergic individuals, regardless of their specific allergies. ... lead author of the study. We presupposed that we ...
... Makes a Lot of Noise has had to turn it ... effect this week . But where there are 8,000,000 New ... of Environmental Protection has a phone line, 311, for quality-of-life ... callers say, is distracting, annoying, shrill, dull or rattling -- ...
... after tests on three dead swans in the northeast confirmed an ... fatal to humans. ,"France is not threatened by ... moment, a human contamination from the H5N1 virus," Health Minister Roselyne ... as the great flu epidemic that followed the war of 1914, ...
Cached Medicine News:Health News:EU Aims to Shake Up Wine Industry With Root-and-branch Reform 2Health News:Cat Exposure Increases Bronchial Responsiveness 2Health News:New York, the City That Roars 24/7, is Forced to Quiet Down 2Health News:New York, the City That Roars 24/7, is Forced to Quiet Down 3Health News:France Steps Up Vigilance After Bird Flu Outbreak 2
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... applications made a lot of progress in the ... are now accepted in high-reliability environments, and are ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... Aug. 30 Hologic, Inc. (Nasdaq: HOLX ... Executive Officer, will present at the 2010 Morgan Stanley ... 2:45 p.m. (Eastern). Interested parties are invited ... investor presentation on the investor section of the company,s ...
... AMEX: DDD ) today announced that it has ... support for the Company,s new line of extended-release nutritional and ... www.emersongroup.com ), headquartered in Wayne, Pa., is a consumer products ... to companies in the United States market.  ...
Cached Medicine Technology:SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products 2SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: